Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2018.03.005
Abstract: Metastatic melanoma is a least common form of cancer as it accounts only for 1% of all cancer cases. But, it is most deadly in nature and is haunting mankind for long emotionally as well… read more here.
Keywords: melanoma; braf mek; mek inhibitors; mek ... See more keywords
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.05.036
Abstract: INTRODUCTION Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance mechanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR. However, the therapeutic effect of combining dabrafenib and… read more here.
Keywords: braf v600e; dabrafenib trametinib; v600e mutation; v600e ... See more keywords
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2019.1635487
Abstract: Abstract Objective: The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB,… read more here.
Keywords: treatment; cost effectiveness; cost; dabrafenib trametinib ... See more keywords
The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1390562
Abstract: ABSTRACT Introduction: The introduction of BRAF and MEK inhibitors into clinical practice improved the prognosis of metastatic melanoma patients. The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown its superiority to single… read more here.
Keywords: melanoma; treatment; safety; efficacy ... See more keywords
Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000429
Abstract: Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2–6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intracranial responses… read more here.
Keywords: patients brain; braf mutated; inhibition; mutated melanoma ... See more keywords
Connective tissue panniculitis and vitiligo in a with patient stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000787
Abstract: The combination of BRAF and MEK inhibitors, such as dabrafenib and trametinib, respectively, is an established treatment option for patients with advanced BRAFV600-mutated melanoma. With the wide adoption of these therapies, a range of cutaneous… read more here.
Keywords: combination; achieving complete; melanoma; stage melanoma ... See more keywords
Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000831
Abstract: The effect of serine/threonine-protein kinase B-Raf/mitogen-activated protein kinase (BRAF/MEK) inhibitors on the immune system is not clearly described, but rare cases of autoimmune phenomena have been reported. The clinical case we present below is the… read more here.
Keywords: necrotizing myopathy; immune mediated; braf; mek inhibitors ... See more keywords
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
Sign Up to like & getrecommendations! Published in 2023 at "Melanoma research"
DOI: 10.1097/cmr.0000000000000888
Abstract: BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-V600 mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine… read more here.
Keywords: world; retrospective observational; melanoma; discontinuation ... See more keywords
Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000012751
Abstract: Rationale: BRAF and MEK inhibitors (BRAF/MEKi) are targeted therapy for proto-oncogene BRAF mutated metastatic unresectable melanoma. Compared to monotherapy, an increased cardiovascular toxicity is reported with the combination of Dabrafenib and Trametinib. This case report… read more here.
Keywords: treatment; tamponade induced; therapy; tamponade ... See more keywords
Dabrafenib- and trametinib-associated glomerular toxicity
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028485
Abstract: Abstract Rationale: Combined treatment with dabrafenib, a B-RAF inhibitor, and trametinib, a mitogen-activated protein kinase inhibitor, is an effective option for patients with metastatic melanoma. A few cases of acute kidney injury associated with tubulointerstitial… read more here.
Keywords: dabrafenib; kidney; dabrafenib trametinib; metastatic melanoma ... See more keywords
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3579
Abstract: Purpose: The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E–mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1… read more here.
Keywords: trametinib panitumumab; patients colorectal; cancer; colorectal cancer ... See more keywords